drugset / Trial / NCT02229773
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
Lipid lowering effect, investigation of pharmacodynamics (inhibition of oxidosqualene cyclase, monoepoxysqualene (MES) as marker), safety / tolerability and preliminary pharmacokinetics
Timeline
- Start
- 2000-01
- Primary completion
- 2000-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIBB 1464 | Unknown | 0.25 mg | Oral |
| Subject | BIBB 1464 | Unknown | 0.5 mg | Oral |
| Subject | BIBB 1464 | Unknown | 1 mg | Oral |
| Comparator | Pravastatin | Small molecule | 20 mg | Oral |
Indications
No indication recorded.